A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This study is conducted to evaluate the safety and tolerability of the drug product sNN0031, containing Platelet Derived Growth Factor (PDGF), when administered directly into one of the fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed® II pump. Patients with a diagnosis of Parkinson\'s disease will be enrolled.
Epistemonikos ID: 27edd919a3ea64609d1088652347c614ca68f92b
First added on: May 05, 2024